Jazz Presents New Xywav Data at SLEEP 2026 Meeting
DUBLIN, Ireland, June 16, 2026 Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new...
Clinical Research
Advertisement
Akston’s AKS-699 Demonstrates One-Year Pruritus Control with Fewer Treatments
BEVERLY, Mass., June 16, 2026 Akston Biosciences Corporation has announced promising preclinical data demonstrating that its investigational immunotherapeutic AKS-699...
SonoClear Study Selected for EANS 2026 Oral Presentation
OSLO, Norway, June 16, 2026 SonoClear AS has announced that findings from its pivotal multicenter study evaluating the SonoClear®...
Nervonik Completes First Human Nerve Sensing Study
LOS ANGELES, June 16, 2026 Nervonik Inc., a clinical-stage medical device company focused on next-generation neuromodulation technologies, has announced...
Optimi Health Launches Standardized Psilocybin Microdose Capsules for Clinical Research
VANCOUVER, British Columbia, June 16, 2026 Optimi Health Corp. has announced the commercial production of two new standardized microdose...
Advertisements
Takeda Oveporexton Shows Broad Benefits in Narcolepsy
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 15, 2026 Takeda has unveiled new pivotal Phase 3 data demonstrating that oveporexton...
Nabsys and LUMC Advance FSHD Research With Genome Mapping
PROVIDENCE, R.I., June 15, 2026 Nabsys 2.0, LLC has announced a strategic research collaboration with Leiden University Medical Center...
Neurocrine’s CRENESSITY Delivers Two-Year Cardiometabolic Benefits in Adult CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
Bambusa Therapeutics Reports Positive Phase 1 BBT002 Data at EAACI 2026
BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary results from the multiple ascending dose (MAD) cohorts of...
Neurocrine Reports Two-Year CRENESSITY Data Showing Improved Growth in Pediatric CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has presented new two-year data from its Phase 3 CAHtalyst® Pediatric study,...
Advertisement
